CN104662017A - 酰胺衍生物及其作为卢立康唑药物制剂的稳定性指标的用途 - Google Patents

酰胺衍生物及其作为卢立康唑药物制剂的稳定性指标的用途 Download PDF

Info

Publication number
CN104662017A
CN104662017A CN201380047770.5A CN201380047770A CN104662017A CN 104662017 A CN104662017 A CN 104662017A CN 201380047770 A CN201380047770 A CN 201380047770A CN 104662017 A CN104662017 A CN 104662017A
Authority
CN
China
Prior art keywords
luliconazole
pharmaceutical
amide derivative
preparation
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380047770.5A
Other languages
English (en)
Chinese (zh)
Inventor
增田孝明
山口博志
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pola Pharma Inc
Nihon Nohyaku Co Ltd
Original Assignee
Pola Pharma Inc
Nihon Nohyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pola Pharma Inc, Nihon Nohyaku Co Ltd filed Critical Pola Pharma Inc
Publication of CN104662017A publication Critical patent/CN104662017A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201380047770.5A 2012-09-14 2013-02-19 酰胺衍生物及其作为卢立康唑药物制剂的稳定性指标的用途 Pending CN104662017A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012202696A JP5460797B1 (ja) 2012-09-14 2012-09-14 アミド誘導体及び安定性指標としてのその使用
JP2012-202696 2012-09-14
PCT/JP2013/055025 WO2014041825A1 (en) 2012-09-14 2013-02-19 Amide derivative and use of the same as stability index of a luliconazole pharmaceutical formulation

Publications (1)

Publication Number Publication Date
CN104662017A true CN104662017A (zh) 2015-05-27

Family

ID=47884458

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380047770.5A Pending CN104662017A (zh) 2012-09-14 2013-02-19 酰胺衍生物及其作为卢立康唑药物制剂的稳定性指标的用途

Country Status (7)

Country Link
US (1) US9145401B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2895480A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP5460797B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN104662017A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2015DN02930A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2612557C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2014041825A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117091A2 (en) 2009-04-09 2010-10-14 Pola Pharma Inc. Antimycotic pharmaceutical composition
KR101409789B1 (ko) 2009-04-09 2014-06-19 니혼노야쿠가부시키가이샤 항진균성 약제학적 조성물
US8952044B2 (en) 2009-08-25 2015-02-10 Pola Pharma Inc. Antimycotic pharmaceutical composition
CN102933201B (zh) 2010-06-11 2015-12-16 宝丽制药股份有限公司 抗真菌药物组合物
WO2014041846A1 (en) 2012-09-14 2014-03-20 Pola Pharma Inc. Use of surface free energy for differential evaluation of crystal, crystal evaluated on basis of surface free energy as index, and phrmaceutical composition prepared by containing the crystal
EP2895479A1 (en) 2012-09-14 2015-07-22 Pola Pharma Inc. Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal
EP2895165B1 (en) 2012-09-14 2016-12-14 Pola Pharma Inc. Crystal and pharmaceutical preparation containing the same crystal
JP5589110B1 (ja) 2013-03-08 2014-09-10 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
JP5680161B1 (ja) 2013-09-06 2015-03-04 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
JP5587488B1 (ja) * 2013-12-12 2014-09-10 株式会社ポーラファルマ ルリコナゾールを含有する製剤の評価方法及び指標物質
JP5926756B2 (ja) * 2014-03-26 2016-05-25 株式会社ポーラファルマ ルリコナゾールを含有する製剤の評価方法及び指標物質
JP5623671B1 (ja) * 2014-07-23 2014-11-12 株式会社ポーラファルマ ルリコナゾールを含有する製剤の評価方法及び指標物質
US10703744B2 (en) * 2014-12-12 2020-07-07 Glenmark Life Sciences Limited Process for preparation of luliconazole
JP7259873B2 (ja) * 2019-02-07 2023-04-18 株式会社島津製作所 分析方法、分析装置およびプログラム

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2005958A1 (en) * 2006-03-08 2008-12-24 Nihon Nohyaku Co., Ltd. External pharmaceutical composition
WO2011155640A1 (en) * 2010-06-11 2011-12-15 Pola Pharma Inc. Antimycotic pharmaceutical composition
CN102395274A (zh) * 2009-02-13 2012-03-28 托派卡医药股份有限公司 抗真菌制剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3081766B2 (ja) 1994-05-06 2000-08-28 東興薬品工業株式会社 角質貯留型抗真菌外用組成物
KR100386491B1 (ko) 1995-07-08 2003-08-21 니혼노야쿠가부시키가이샤 항진균제,이를위한화합물및이의제조방법
JP2002114680A (ja) 2000-07-31 2002-04-16 Nippon Nohyaku Co Ltd 抗真菌剤
WO2007102243A1 (ja) 2006-03-08 2007-09-13 Nihon Nohyaku Co., Ltd. 外用の医薬組成物
AU2006339841B2 (en) 2006-03-08 2012-08-30 Nihon Nohyaku Co., Ltd. Pharmaceutical composition for external use
EP2191826B1 (en) 2007-09-05 2017-03-08 Pola Pharma Inc. Pharmaceutical composition
JP5345937B2 (ja) * 2007-09-05 2013-11-20 株式会社ポーラファルマ 抗真菌組成物
JP5453093B2 (ja) 2007-09-05 2014-03-26 株式会社ポーラファルマ 抗真菌医薬組成物
WO2010117091A2 (en) 2009-04-09 2010-10-14 Pola Pharma Inc. Antimycotic pharmaceutical composition
KR101409789B1 (ko) 2009-04-09 2014-06-19 니혼노야쿠가부시키가이샤 항진균성 약제학적 조성물
US8952044B2 (en) 2009-08-25 2015-02-10 Pola Pharma Inc. Antimycotic pharmaceutical composition
EP2895165B1 (en) 2012-09-14 2016-12-14 Pola Pharma Inc. Crystal and pharmaceutical preparation containing the same crystal
WO2014041846A1 (en) 2012-09-14 2014-03-20 Pola Pharma Inc. Use of surface free energy for differential evaluation of crystal, crystal evaluated on basis of surface free energy as index, and phrmaceutical composition prepared by containing the crystal
EP2895479A1 (en) 2012-09-14 2015-07-22 Pola Pharma Inc. Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal
IN2015DN02377A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 2012-09-14 2015-09-04 Pola Pharma Inc
JP5589110B1 (ja) 2013-03-08 2014-09-10 株式会社ポーラファルマ 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物
JP5587488B1 (ja) * 2013-12-12 2014-09-10 株式会社ポーラファルマ ルリコナゾールを含有する製剤の評価方法及び指標物質

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2005958A1 (en) * 2006-03-08 2008-12-24 Nihon Nohyaku Co., Ltd. External pharmaceutical composition
EP2005958A4 (en) * 2006-03-08 2010-09-15 Nihon Nohyaku Co Ltd TOPICAL PHARMACEUTICAL COMPOSITION
CN102395274A (zh) * 2009-02-13 2012-03-28 托派卡医药股份有限公司 抗真菌制剂
WO2011155640A1 (en) * 2010-06-11 2011-12-15 Pola Pharma Inc. Antimycotic pharmaceutical composition

Also Published As

Publication number Publication date
JP2014058449A (ja) 2014-04-03
US9145401B2 (en) 2015-09-29
JP5460797B1 (ja) 2014-04-02
RU2015113587A (ru) 2016-11-10
IN2015DN02930A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-09-18
WO2014041825A1 (en) 2014-03-20
EP2895480A1 (en) 2015-07-22
US20150191456A1 (en) 2015-07-09
RU2612557C2 (ru) 2017-03-09

Similar Documents

Publication Publication Date Title
CN104662017A (zh) 酰胺衍生物及其作为卢立康唑药物制剂的稳定性指标的用途
EP1765788B1 (de) 3-aminoindazole derivate und ihre verwendung zur behandlung sgk-bedingten krankheiten
EP1984324B1 (de) Mandelsäurehydrazide
JP7450559B2 (ja) 疾患の処置のためのｋｄｍ１ａ阻害剤
US20040204404A1 (en) Human N-type calcium channel blockers
DE60030574T2 (de) Fünfgliedrige derivate von heterozyklen und ihre verwendung als monoaminoxidase-inhibitoren
CN112771027A (zh) 溶血磷脂酸受体拮抗剂及其制备方法
CN104619320A (zh) 含有卢立康唑的药物组合物
CN105592888A (zh) 用于治疗疾病的kdm1a抑制剂
DK2820013T3 (en) Liver X Receptor (LXR) modulators for the treatment of dermal diseases, disorders and conditions
CA2060750A1 (fr) Derives bicycliques azotes, leur procede de preparation, nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
KR102598775B1 (ko) Ｒｏｒ­감마 조절제
JP5587488B1 (ja) ルリコナゾールを含有する製剤の評価方法及び指標物質
CA2770767A1 (en) Bicyclic heteroaryl inhibitors of pde4
WO2006105850A1 (de) Acylhyclrazide als kinase inhibitoren insbesondere für sgk
Kumari et al. Design, synthesis, molecular docking and dynamic studies of novel thienopyrimidine analogs linked to 1, 2, 3-triazole-bearing acetamide derivatives as anti-oxidant agents
JP4965428B2 (ja) セミカルバジド誘導体を含むフリーラジカル消去剤
EP1761482A1 (de) Ortho-substituierte (3-hydroxyphenyl)-essigsäure benzyliden-hydrazide
DE69816456T2 (de) Verwendung von 4-substituierten tetrahydropyridinen zur herstellung eines arzneimittels mit wirkung auf tgf-beta-1
JP5623671B1 (ja) ルリコナゾールを含有する製剤の評価方法及び指標物質
TW401415B (en) Enantiomerically pure (+)-liarozole
EP2924028A1 (en) Trpv-1 receptor antagonist compound derived from 1,3,4-thiadiazole alkylamides and chalcones
JP5926756B2 (ja) ルリコナゾールを含有する製剤の評価方法及び指標物質
Kataria et al. Synthesis of some new 2-(substituted-phenyl)-5-(N, N-diphenylaminomethyl)-1, 3, 4-oxadiazoles: a safer anti-inflammatory and analgesic agents
JP2015027983A (ja) 結晶及び該結晶を含有してなる医薬製剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20150527

RJ01 Rejection of invention patent application after publication